1415120-49-8

Basic information

• Product Name: C₅₆H₆₄N₈O₆
• Synonyms: C₅₆H₆₄N₈O₆
• CAS NO: 1415120-49-8
• Molecular Weight: 945.174
• Mol File: 1415120-49-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₅₆H₆₄N₈O₆(CAS DataBase Reference)
• NIST Chemistry Reference: C₅₆H₆₄N₈O₆(1415120-49-8)
• EPA Substance Registry System: C₅₆H₆₄N₈O₆(1415120-49-8)

Safety Data

• Hazardous Substances Data: 1415120-49-8(Hazardous Substances Data)

Upstream product

• 1228552-27-9 ((S)-1-{(S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1255936-24-3 4-(4-bromophenyl)-2-[(2S)-2-pyrrolidinyl]-1H-imidazole 
• 1007882-04-3 (S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylic acid tert-butyl ester 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 196316-30-0 4,16-dibromo[2.2]paracyclophane 
• 1228553-33-0 [(S)-2-methyl-1-((S)-2-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carbonyl)propyl]carbamic acid methyl ester 
• 1633-22-3 [2.2]Paracyclophan 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Relevant articles and documents

SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I [in-line-formulae]D-M-D??(Formula I)[/in-line-formulae] useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/ and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.